Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minehiko Inomata

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Anticancer Research|September 16, 2016
Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung CancerMinehiko Inomata, Kazuki Shimokawa, Kotaro Tokui, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|June 22, 2011
[Synchronous pulmonary hamartoma and lung cancer in a young patient]Seisuke Okazawa, Yukio Kawagishi, Minehiko Inomata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 10, 2017
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity]Hiroaki Tanaka, Minehiko Inomata, Ryuji Hayashi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2014
[Efficacy and toxicity of pemetrexed monotherapy for previously untreated elderly patients with non-squamous cell lung cancer with wild-type(or unknown)EGFR status]Minehiko Inomata, Ryuji Hayashi, Kotaro Tokui, et al.
Tumori|October 3, 2015
Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicinMinehiko Inomata, Ryuji Hayashi, Kotaro Tokui, et al.
Oncology Letters|July 10, 2023
A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202Minehiko Inomata, Yosuke Kawashima, Ryota Saito, et al.
Tumori|October 25, 2014
Outcome and prognostic factors in patients with small cell lung cancer who receive third-line chemotherapyMinehiko Inomata, Ryuji Hayashi, Kotaro Tokui, et al.
The Journal of International Medical Research|May 31, 2015
Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective studyKensuke Suzuki, Hideaki Furuse, Takeshi Tsuda, et al.
Pathology Oncology Research : POR|September 21, 2018
Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor TherapyMinehiko Inomata, Takahiro Hirai, Zenta Seto, et al.
Diagnostics (Basel, Switzerland)|December 1, 2020
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI TherapyMinehiko Inomata, Kenji Azechi, Naoki Takata, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Anticancer Research|September 16, 2016
Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung CancerMinehiko Inomata, Kazuki Shimokawa, Kotaro Tokui, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|June 22, 2011
[Synchronous pulmonary hamartoma and lung cancer in a young patient]Seisuke Okazawa, Yukio Kawagishi, Minehiko Inomata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 10, 2017
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity]Hiroaki Tanaka, Minehiko Inomata, Ryuji Hayashi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2014
[Efficacy and toxicity of pemetrexed monotherapy for previously untreated elderly patients with non-squamous cell lung cancer with wild-type(or unknown)EGFR status]Minehiko Inomata, Ryuji Hayashi, Kotaro Tokui, et al.
Tumori|October 3, 2015
Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicinMinehiko Inomata, Ryuji Hayashi, Kotaro Tokui, et al.
Oncology Letters|July 10, 2023
A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202Minehiko Inomata, Yosuke Kawashima, Ryota Saito, et al.
Tumori|October 25, 2014
Outcome and prognostic factors in patients with small cell lung cancer who receive third-line chemotherapyMinehiko Inomata, Ryuji Hayashi, Kotaro Tokui, et al.
The Journal of International Medical Research|May 31, 2015
Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective studyKensuke Suzuki, Hideaki Furuse, Takeshi Tsuda, et al.
Pathology Oncology Research : POR|September 21, 2018
Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor TherapyMinehiko Inomata, Takahiro Hirai, Zenta Seto, et al.
Diagnostics (Basel, Switzerland)|December 1, 2020
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI TherapyMinehiko Inomata, Kenji Azechi, Naoki Takata, et al.
Pageof 7